Medical

Glenmark Pharmaceuticals recently said that a Phase 3 study comparing Ryaltris olopatadine hydrochloride to placebo in seasonal allergic rhinitis patients aged 6 up to 12 years achieved its primary endpoint. The 14-day study, which enrolled 446 patients, demonstrated a statistically significant improvement in average Reflective Total Nasal Symptom Score (rTNSS), with … [Read more...] about Phase 3 study of Ryaltris nasal spray for treatment of allergic rhinitis in pediatric patients met primary endpoint

Verona Pharma said that it has initiated a Phase 2b dose-ranging study of RPL554 nebulized ensifentrine for the treatment of COPD, with results expected by the end of 2019. The company, which reported positive results from a Phase 2 study of an ensifetrine DPI in March 2019, said that it also expects to start a Phase 2 trial of an ensifetrine MDI for COPD this quarter … [Read more...] about Verona initiates Phase 2b study of nebulized ensifentrine for COPD

GlaxoSmithKline and Innoviva have announced that the Phase 3 CAPTAIN (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler) study comparing the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI to the Relvar/Breo Ellipta FF/VI DPI in patients with uncontrolled asthma met its primary endpoint. The CAPTAIN … [Read more...] about Phase 3 study of Trelegy Ellipta for the treatment of asthma meets primary endpoint

Marinomed Biotech has announced that a Phase 3 trial of Budesolv budesonide nasal spray has met its primary endpoint. Without providing any specific data, the company said that, "The top line results are now available and show that Budesolv achieves at least the same effect as the product which is currently on the market, with a significantly lower dose." According to … [Read more...] about Marinomed Biotech says Phase 3 trial of Budesolv nasal spray met primary endpoint

Novus Therapeutics said that two Phase 1 trials of its OP0201 intranasal MDI, which is in development for otitis media, both met their primary endpoints. In one of the studies, healthy adults received either a single 20 mg dose of OP0201 or placebo and were then exposed to pressure changes in a pressure chamber. In the other, adults with acute otitis media received 20 … [Read more...] about Phase 1 trials of intranasal MDI for otitis media meet primary endpoints

The UK's National Institute for Health Care and Excellence (NICE) has issued a new "patient decision aid" that emphasizes that a metered dose inhaler "contains propellant, so it has a higher carbon footprint than a DPI." In a statement, NICE explains, "Where several inhalers could be viable options, patients can opt for the more environmentally friendly option, which … [Read more...] about NICE suggests patients use “greener” DPIs instead of MDIs

VistaGen Therapeutics has presented new data from a Phase 3 study of PH94B nasal spray for the treatment of social anxiety disorder (SAD) at the 2019 Anxiety and Depression Association of America (ADAA) Annual Conference. VistaGen acquired the rights to PH948B from Pherin Pharmaceuticals in September 2018. According to Vistagen, patients who received PH94B … [Read more...] about VistaGen presents new data from Phase 3 study of PH94B nasal spray for social anxiety disorder

Savara has announced the initiation of the Phase 2a ENCORE study of its Molgradex inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection in cystic fibrosis patients. The company is also developing Molgradex for the treatment of NTM lung infections in non-CF patients and … [Read more...] about Savara begins Phase 2a trial of Molgradex for the treatment of NTM lung infection in CF patients